Company Overview
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
Why Investors Should Care
Revenue has grown at a 18.0% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.14.
Recent Developments
- Nov 2025 Revenue of $83.98M (+54.0% YoY); net profit $-264.46M.
- Trailing 12 Months Year-on-year growth — revenue -79.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 18.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 18.00% |
| 1 Year: | -79.50% |
Stock Price Performance
| 1 Year: | +87.94% |
| 6 Months: | +29.76% |
| 3 Months: | +46.32% |
| 1 Month: | +40.71% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)67.77 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 18.0% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NRIX Nurix Therapeutics, Inc. R2K | 23.85 | -6.89 | $2.48B | 0.00% | -47.48% | -80.30% | 18.00% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,156.63 | 41.13 | $1.03T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 247.02 | 28.66 | $594.63B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.11 | 119.08 | $431.29B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 418.52 | 31.54 | $380.08B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 123.61 | 34.82 | $305.29B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 168.37 | 26.10 | $261.12B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 535.29 | 29.40 | $198.93B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 358.32 | 24.92 | $193.39B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Feb 2019 | May 2019 | Aug 2019 | Nov 2019 | Feb 2020 | May 2020 | Aug 2020 | Nov 2020 | Feb 2021 | May 2021 | Aug 2021 | Feb 2022 | May 2022 | Aug 2022 | Feb 2023 | May 2023 | Aug 2023 | Feb 2024 | May 2024 | Aug 2024 | Feb 2025 | May 2025 | Aug 2025 | Feb 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 30.68M | 18.47M | 16.59M | 12.09M | 12.59M | 18.45M | 44.06M | 7.89M | 6.25M |
| Operating Income | - | - | -2.61M | - | -12.55M | -13.23M | -19.19M | - | -24.52M | -26.41M | -29.00M | -42.74M | -45.72M | -46.72M | -42.95M | -26.77M | -40.01M | -45.22M | -48.54M | -54.61M | -62.86M | -48.32M | -91.39M | -92.50M |
| Net Income | -2.69M | -3.07M | -2.43M | -13.52M | -12.39M | 7.58M | -18.52M | -19.91M | -24.27M | -26.38M | -28.84M | -42.53M | -45.40M | -45.71M | -40.73M | -24.28M | -36.98M | -41.52M | -44.55M | -48.96M | -56.35M | -43.46M | -86.42M | -87.17M |
| Diluted EPS | - | - | - | - | - | 0.00 | -1.09 | - | - | -0.60 | -0.65 | -0.95 | -1.01 | -0.90 | -0.75 | -0.45 | -0.68 | -0.76 | -0.71 | -0.67 | -0.67 | -0.52 | -1.03 | -0.79 |
| R&D Expense | - | - | 11.01M | - | 12.97M | 14.14M | 18.94M | - | 23.00M | 25.99M | 30.91M | 43.14M | 47.49M | 47.76M | 45.82M | 45.76M | 47.86M | 50.01M | 48.92M | 55.48M | 69.66M | 78.10M | 86.12M | 84.14M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Nov 2019 | Nov 2020 | Nov 2021 | Nov 2022 | Nov 2023 | Nov 2024 | Nov 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 31.11M | 17.82M | 29.75M | 38.63M | 76.99M | 54.55M | 83.98M |
| Operating Income | -22.24M | -64.98M | -117.89M | -183.87M | -155.06M | -213.03M | -285.67M |
| Net Income | -21.70M | -43.24M | -117.19M | -180.36M | -143.95M | -193.57M | -264.46M |
| Diluted EPS | - | - | -2.73 | -3.71 | -2.65 | -2.88 | -3.05 |
| R&D Expense | 45.02M | 66.49M | 116.43M | 184.50M | 189.15M | 221.63M | 316.90M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Nov 2018 | Nov 2019 | Nov 2020 | Nov 2021 | Nov 2022 | Nov 2023 | Nov 2024 | Nov 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 44.05M | 396.34M | 476.77M | 416.76M | 355.60M | 669.34M | 688.13M |
| Total Equity | -36.85M | -57.71M | 290.27M | 342.30M | 303.70M | 200.49M | 526.99M | 538.75M |
| Cash & Equivalents | - | 34.82M | 119.36M | 80.51M | 64.47M | 54.63M | 110.00M | 246.96M |
| Total Liabilities | - | 53.57M | 106.07M | 134.47M | 113.06M | 155.10M | 142.35M | 149.39M |
| Current Liabilities | - | 16.14M | 44.54M | 66.26M | 70.66M | 86.96M | 95.85M | 86.47M |
Cash Flows (Annual)
Figures in USD.
| Metric | Nov 2019 | Nov 2020 | Nov 2021 | Nov 2022 | Nov 2023 | Nov 2024 | Nov 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 601.00K | -80.00K | -84.36M | -159.81M | -81.36M | -172.58M | -249.47M |
| Investing Cash Flow | 8.50M | -254.40M | -108.25M | 27.20M | 68.30M | -257.71M | 147.85M |
| Financing Cash Flow | 126.00K | 339.02M | 153.88M | 117.19M | 3.22M | 485.67M | 238.64M |
| Capital Expenditure | -1.65M | -4.55M | -5.66M | -12.24M | -8.40M | -9.27M | -14.00M |
| Free Cash Flow | -1.05M | -4.63M | -90.03M | -172.05M | -89.77M | -181.86M | -263.47M |
Ratios (Annual)
Figures in %.
| Metric | Nov 2019 | Nov 2020 | Nov 2021 | Nov 2022 | Nov 2023 | Nov 2024 | Nov 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | -71.5% | -364.7% | -396.3% | -476.0% | -201.4% | -390.5% | -340.2% |
| Net Margin % | -69.7% | -242.7% | -393.9% | -466.9% | -187.0% | -354.9% | -314.9% |
| ROE % | 37.6% | -14.9% | -34.2% | -59.4% | -71.8% | -36.7% | -49.1% |
| ROCE % | -79.7% | -18.5% | -28.7% | -53.1% | -57.7% | -37.1% | -47.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 8.60% | 8.93M | $208.95M |
| 2 | Redmile Group, LLC | 7.45% | 7.73M | $181.03M |
| 3 | Vestal Point Capital, LP | 6.26% | 6.50M | $152.16M |
| 4 | Deep Track Capital, Lp | 6.11% | 6.35M | $148.54M |
| 5 | FMR, LLC | 5.34% | 5.54M | $129.72M |
| 6 | State Street Corporation | 4.95% | 5.14M | $120.36M |
| 7 | Morgan Stanley | 4.75% | 4.93M | $115.46M |
| 8 | Baker Bros. Advisors, LP | 4.49% | 4.66M | $109.06M |
| 9 | Vanguard Capital Management LLC | 4.27% | 4.43M | $103.64M |
| 10 | General Atlantic, L.P. | 3.95% | 4.10M | $96.02M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NRIX
Nurix Therapeutics (NRIX) Stock Looks Pricey After Roche Deal And Weaker Quarter - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWmhxdkpuR25PTXQ0WHpzQkplS2txdzNiSTdBby1OUHNLdExSS0xtNmo3c3BMNWhLZmFWckx5MzYtZlhjdjNLeHp5UDhrMndpdDFVbmlIa3g2MWJseXBjSzhpTGhZVmo5ZkhRYlhFSHJoV0ctVnIxdmFBLVpnaWltQlpISU9OLUpMLXkwM1…
Earnings Preview: Nurix Therapeutics, Inc. (NRIX) Q2 Earnings Expected to Decline - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxQUU9SM2pIVDFoU1hWSTl5N29TWXgxU1BhZVRNbExhRVBiMllFRjVoV191WGprRS1NV3BSek4xdjhieHphcUp2Z1ByVkFKbjhqdmlhZlpPTHhfYkctTEFxdjE3cjFnSzRoSVYtRlZvQXZZTjBJSjVoZEd1ZlRwVXUyX08zNWlFSEw2TFA1Zj…
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxPUDJQM21TRWJuWk5KT2doTDU4X2pUZ3NMRWhITjM3MmwwOHdVVUtDcHVFekh5ZVVjWGpnd1B1bkJFUHBYOVpJRmVjcXVoNXQyTmYyNUtmNnlteGlWWnBUQ21aSVQ5ZW1pcENGQ3NZdUtaWEs3OTBoRmxsYUFuY1JKc05YYlZubzA1Y29jc2…
$NRIX stock is down 9% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxNUkhTME9LLUZUcXpkZmtBYXJVQjZVV3VFRmFnSHMyODB3MHRmdVdnRVpzQi0zSU0zU05fVDhGUmFxY1VMaVlYT2J1Z1hpLTJqS1hSR1lPSTlsNFJ3M2FHOG81VzlrcGRiOHM5T2JRcjhGTkkyTmtqbThiQzVtdzZXaE5LVDQySGl1YV9kcW…
NRIX Maintained by Mizuho -- Price Target Raised to $34.00 - GuruFocus
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxPbmI1cnVoZVFEOWJsdFRvdVZQemwxMEtGNmQzS0VIQ3ZoemRYeldGU1ZFUnk1MF9Ic0pkVHZoRmVQeXoyQkVSV2hyZWdoUzNIdTVLeEhKVlVSVnpKN2RwNFB5VGpWTDgyVTRVQUJoZ2M3dWdfLWdjMWJkOHFJWjhfOHY5MHJ3ajN3eTRnNU…
NRIX Stock Surges Nearly 70% Premarket Today – Roche And Nurix’s Blood Cancer Drug Collaboration Can Tap A $41B Market - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiiwJBVV95cUxQUHVqSF9TMndkbWxqSXBSSEZHVmlkMFdFb01NLW5McGd2NlJKNEZaSTNERjZNWmlVLUxRVWQ0STJCTG9OLWZObmtUN1ZlOXJ1TEhEbi1ZTUJzV2Mwc2dEaTU5OVgwZEVodkZGZDBIckwyWU1kZlZ3dlY4VlhuMGMzSllpd0pXMk0yUHR3cj…
NRIX — Frequently Asked Questions
What is the current share price of Nurix Therapeutics, Inc. (NRIX)?
As of 2026-07-15 16:51 PDT, Nurix Therapeutics, Inc. (NRIX) trades at $23.85 on NasdaqGM. Its 52-week range is $8.24 to $24.69.
What is the market capitalisation of NRIX?
Nurix Therapeutics, Inc. (NRIX) has a market capitalisation of $2.48B on NasdaqGM.
What is the P/E ratio of NRIX?
NRIX trades at a trailing price-to-earnings (P/E) ratio of -6.89. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 5.03.
What is the return on equity (ROE) of NRIX?
NRIX has a return on equity (ROE) of -80.30%. Its return on capital employed (ROCE) is -47.48%.
Is NRIX a good stock to buy?
This page provides a data-driven analysis of Nurix Therapeutics, Inc. (NRIX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.